Ipamorelin is a growth-hormone secretagogue: it asks the pituitary to release a GH pulse rather than replacing GH directly (unlike HGH). The signal passes through the body's own GH-control system, including the feedback brake that ends the pulse. Within GH peptides it's the modern GHRP-style option — older GHRP-2/GHRP-6 drive a strong pulse but bring more hunger, flushing, cortisol, ACTH, and prolactin; ipamorelin keeps the pulse while reducing that noise. The caveat: its popular at-home use is a peptide-user translation — the published human efficacy program tested short-course IV use for postoperative ileus and missed its main endpoint.
What Is Ipamorelin?
A synthetic five-amino-acid peptide (not an amino acid, not GH itself) that activates the ghrelin receptor to trigger GH release. HGH adds GH from outside; ipamorelin asks the pituitary to release its own pulse — shaped by pituitary reserve, sleep timing, food timing, glucose status, and feedback control. It's a pulse peptide, not tonic hormone replacement.
How Ipamorelin Works
It activates the ghrelin receptor on pituitary somatotrophs to release a GH pulse; the downstream IGF-1 rise carries effects into tissue repair, protein turnover, and body composition. Its selectivity is the useful part: in preclinical work it released GH without the cortisol, ACTH, prolactin, LH, FSH, or TSH movement seen with older GHRPs. Insulin and GH pulses oppose each other, so higher insulin blunts the GH response.
Expected Benefits
Best benefit: better overnight recovery when the rest of the system is aligned (deeper sleep, less soreness, stronger morning recovery). Lean-mass support is plausible but not automatic — resistance training and protein decide whether the GH/IGF-1 signal becomes adaptation; without load it can add water/soft weight. Not a primary visceral-fat drug — tesamorelin has the strongest signal there.
What the Evidence Shows
Three layers, not to be collapsed: (1) Pharmacology — human IV PK shows dose-proportional exposure, ~2 h terminal half-life, renal clearance. (2) Selectivity — Raun et al. described it as a selective GH secretagogue with far less stress-hormone/prolactin spillover (the "cleaner GHRP" basis). (3) Human efficacy — the published program tested IV ipamorelin for postoperative ileus; in the Phase 2 proof-of-concept study it was well tolerated but the primary endpoint did not reach significance. That failure doesn't answer whether ipamorelin helps recovery in peptide users — but the absence of a long-term body-composition trial means claims should be framed as mechanism-plus-practice, not RCT-proven.
Ipamorelin vs GHRP-2 and GHRP-6
Treat ipamorelin as the modern version of the older injectable GHRP idea. GHRP-2 drives a strong pulse but raises cortisol and prolactin; GHRP-6 is appetite-forward (useful only when appetite stimulation is the goal). Ipamorelin isn't side-effect-free, but it's the better default when the desired signal is a short GH pulse without deliberate hunger drive or extra stress-hormone activation.
Side Effects and Safety
Most side effects come from the injection itself or too much GH/IGF-1 for the user's context. Injection-site irritation (redness, itch, welt, warmth) is often local mast-cell activation, not a bad vial. Water retention is the more important systemic sign — puffy fingers, ankle swelling, numbness, or carpal-tunnel-like tingling suggest the signal is too high. GH-axis activation can worsen insulin sensitivity in vulnerable users. Hard cautions: active malignancy, pregnancy, heart-failure history, recent MI, unstable CVD, uncontrolled diabetes, significant edema, disrupted pituitary anatomy.
Histamine, flushing, and injection-site reactions
Itchy bumps, warmth, and brief flushing are usually a local mast-cell response (MRGPRX2) to peptide chemistry/concentration, not true allergy. Wheal-and-flare: itchy bump at the site (local activation). Systemic flushing: warmth/redness across face/neck/chest (faster exposure or lower threshold). Allergic-type symptoms: hives away from the site, facial swelling, throat tightness, wheezing — stop and evaluate clinically.